3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
3
Dermatologic
3
Gynecologic
2
Genitourinary
2
Gastrointestinal
2
Thoracic
1
Other hematologic neoplasm
1
Lymphoid
1
Head & Neck
1
CNS
1
Conditions
Squamous Cell Carcinoma of Head and Neck
6
Uterine Cervical Neoplasms
5
Head and Neck Neoplasms
5
Vaginal Neoplasms
4
Penile Neoplasms
4
Oropharyngeal Neoplasms
4
Neoplasm Metastasis
4
Anus Neoplasms
4
Stomach Neoplasms
3
Melanoma
3
Carcinoma, Squamous Cell
3
Carcinoma, Non-Small-Cell Lung
3
Vulvar Neoplasms
2
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Small Cell Lung Carcinoma
2
Salivary Gland Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Merkel Cell
2
Carcinoma, Hepatocellular
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Tongue Neoplasms
1
Thyroid Cancer, Papillary
1
Testicular Neoplasms
1
Testicular Germ Cell Tumor
1
Sarcoma
1
Interventions
pembrolizumab
33
Cetuximab
16
Cisplatin
10
Radiotherapy
8
Paclitaxel
8
Docetaxel
8
atezolizumab
7
Fluorouracil
7
cemiplimab
6
Drug Therapy
6
budigalimab
5
Gemcitabine
5
Cyclophosphamide
5
Blood Specimen Collection
5
trametinib
4
Pemetrexed
4
Nivolumab
4
Magnetic Resonance Spectroscopy
4
Bleomycin
4
Bevacizumab
4
palbociclib
3
fludarabine
3
durvalumab
3
dabrafenib
3
avelumab
3
Trastuzumab
3
Oxaliplatin
3
Interleukin-2
3
Indocyanine Green
3
Immunotherapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
aldesleukin
×
Head & Neck
×
Clear all
NCT02876510
2025-02-04
ACTolog
Immatics US, Inc.
Phase 1
Completed
38 enrolled